AIM: To determine the effect of cisapride on gastrointestinal motility in preterm infants. METHODS:Cisapride (0.2 mg/kg, 8 hourly ) or placebo was given first for seven days in a double blind randomised crossover study of 10 preterm infants. Gastrointestinal motility was assessed on day 3 of each treatment. The half gastric emptying time (GET1/2) was determined by using ultrasonography to measure the decrease in the gastric antral cross sectional area after a feed. The whole gastrointestinal transit time (WGTT) was assessed by timing the transit of carmine red through the gut. Treatments were compared using the Wilcoxon matched pairs signed ranks test. RESULTS:Median (range) birthweight was 1200 (620, 1450) g and postconceptional age 33 (29, 34) weeks at recruitment. GET1/2 was significantly longer during cisapride treatment than during placebo; the median of the differences (95% confidence interval) was 19.2 (11, 30 minutes, p=0.008). WGTT was also longer during cisapride treatment, but the difference was not significant; the median of the differences was 11(-18, 52 hours, p=0.1). CONCLUSIONS:Cisapride delays gastric emptying and may delay WGTT in preterm infants. Its use to promote gastrointestinal motility in this group cannot be recommended.
RCT Entities:
AIM: To determine the effect of cisapride on gastrointestinal motility in preterm infants. METHODS:Cisapride (0.2 mg/kg, 8 hourly ) or placebo was given first for seven days in a double blind randomised crossover study of 10 preterm infants. Gastrointestinal motility was assessed on day 3 of each treatment. The half gastric emptying time (GET1/2) was determined by using ultrasonography to measure the decrease in the gastric antral cross sectional area after a feed. The whole gastrointestinal transit time (WGTT) was assessed by timing the transit of carmine red through the gut. Treatments were compared using the Wilcoxon matched pairs signed ranks test. RESULTS: Median (range) birthweight was 1200 (620, 1450) g and postconceptional age 33 (29, 34) weeks at recruitment. GET1/2 was significantly longer during cisapride treatment than during placebo; the median of the differences (95% confidence interval) was 19.2 (11, 30 minutes, p=0.008). WGTT was also longer during cisapride treatment, but the difference was not significant; the median of the differences was 11(-18, 52 hours, p=0.1). CONCLUSIONS:Cisapride delays gastric emptying and may delay WGTT in preterm infants. Its use to promote gastrointestinal motility in this group cannot be recommended.
Authors: J F Bergmann; O Chassany; P J Guillausseau; M Bayle; S Chagnon; C Caulin; J R Sallenave Journal: Eur J Clin Pharmacol Date: 1992 Impact factor: 2.953
Authors: A Carroccio; G Iacono; G Li Voti; G Montalto; F Cavataio; V Tulone; D Lorello; I Kazmierska; C Acierno; A Notarbartolo Journal: Scand J Gastroenterol Date: 1992-09 Impact factor: 2.423
Authors: T I Omari; C P Barnett; M A Benninga; R Lontis; L Goodchild; R R Haslam; J Dent; G P Davidson Journal: Gut Date: 2002-10 Impact factor: 23.059
Authors: J Tack; M Camilleri; L Chang; W D Chey; J J Galligan; B E Lacy; S Müller-Lissner; E M M Quigley; J Schuurkes; J H De Maeyer; V Stanghellini Journal: Aliment Pharmacol Ther Date: 2012-02-22 Impact factor: 8.171
Authors: Pak C Ng; Cheuk H Lee; Samuel P S Wong; Hugh S Lam; Flora Y B Liu; King W So; Cheuk Y Lee; Tai F Fok Journal: Gastroenterology Date: 2007-03-24 Impact factor: 22.682